235 related articles for article (PubMed ID: 28008178)
41. Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
Teramachi J; Hiasa M; Oda A; Harada T; Nakamura S; Amachi R; Tenshin H; Iwasa M; Fujii S; Kagawa K; Miki H; Kurahashi K; Yoshida S; Endo I; Haneji T; Matsumoto T; Abe M
Br J Haematol; 2018 Feb; 180(4):581-585. PubMed ID: 27748523
[No Abstract] [Full Text] [Related]
42. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
43. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
[TBL] [Abstract][Full Text] [Related]
44. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
45. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
46. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.
An N; Kraft AS; Kang Y
J Hematol Oncol; 2013 Jan; 6():12. PubMed ID: 23360755
[TBL] [Abstract][Full Text] [Related]
47. Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells.
Yu Z; Zhao X; Huang L; Zhang T; Yang F; Xie L; Song S; Miao P; Zhao L; Sun X; Liu J; Huang G
J Biol Chem; 2013 Dec; 288(49):35406-16. PubMed ID: 24142698
[TBL] [Abstract][Full Text] [Related]
48. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.
Mikkers H; Nawijn M; Allen J; Brouwers C; Verhoeven E; Jonkers J; Berns A
Mol Cell Biol; 2004 Jul; 24(13):6104-15. PubMed ID: 15199164
[TBL] [Abstract][Full Text] [Related]
49. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
Meja K; Stengel C; Sellar R; Huszar D; Davies BR; Gale RE; Linch DC; Khwaja A
Br J Haematol; 2014 Oct; 167(1):69-79. PubMed ID: 24975213
[TBL] [Abstract][Full Text] [Related]
50. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway.
Zhu N; Ramirez LM; Lee RL; Magnuson NS; Bishop GA; Gold MR
J Immunol; 2002 Jan; 168(2):744-54. PubMed ID: 11777968
[TBL] [Abstract][Full Text] [Related]
51. CHES1/FOXN3 regulates cell proliferation by repressing PIM2 and protein biosynthesis.
Huot G; Vernier M; Bourdeau V; Doucet L; Saint-Germain E; Gaumont-Leclerc MF; Moro A; Ferbeyre G
Mol Biol Cell; 2014 Mar; 25(5):554-65. PubMed ID: 24403608
[TBL] [Abstract][Full Text] [Related]
52. Persistent activation of STAT3 by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer.
Uddin N; Kim RK; Yoo KC; Kim YH; Cui YH; Kim IG; Suh Y; Lee SJ
Cancer Sci; 2015 Jun; 106(6):718-725. PubMed ID: 25854938
[TBL] [Abstract][Full Text] [Related]
53. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival.
Kim KT; Baird K; Ahn JY; Meltzer P; Lilly M; Levis M; Small D
Blood; 2005 Feb; 105(4):1759-67. PubMed ID: 15498859
[TBL] [Abstract][Full Text] [Related]
54. Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappaB.
Tsatsanis C; Patriotis C; Tsichlis PN
Oncogene; 1998 Nov; 17(20):2609-18. PubMed ID: 9840924
[TBL] [Abstract][Full Text] [Related]
55. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
[TBL] [Abstract][Full Text] [Related]
56. Expression of the PIM2 gene is associated with more aggressive clinical course in patients with chronic lymphocytic leukemia.
Kapelko-Słowik K; Dybko J; Grzymajło K; Jaźwiec B; Urbaniak-Kujda D; Słowik M; Potoczek S; Wołowiec D
Adv Clin Exp Med; 2019 Mar; 28(3):385-390. PubMed ID: 30525315
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1.
Hiromura M; Okada F; Obata T; Auguin D; Shibata T; Roumestand C; Noguchi M
J Biol Chem; 2004 Dec; 279(51):53407-18. PubMed ID: 15459205
[TBL] [Abstract][Full Text] [Related]
58. A regulatory feedback loop between HIF-1α and PIM2 in HepG2 cells.
Yu Z; Zhao X; Ge Y; Zhang T; Huang L; Zhou X; Xie L; Liu J; Huang G
PLoS One; 2014; 9(2):e88301. PubMed ID: 24505470
[TBL] [Abstract][Full Text] [Related]
59. Roles of Pim-3, a novel survival kinase, in tumorigenesis.
Mukaida N; Wang YY; Li YY
Cancer Sci; 2011 Aug; 102(8):1437-42. PubMed ID: 21518143
[TBL] [Abstract][Full Text] [Related]
60. PIM2 Induced COX-2 and MMP-9 expression in macrophages requires PI3K and Notch1 signaling.
Bansal K; Kapoor N; Narayana Y; Puzo G; Gilleron M; Balaji KN
PLoS One; 2009; 4(3):e4911. PubMed ID: 19290049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
